Phase III ADVANCE Study on Otezla's Treatment of Mild Moderate Plaque Psoriasis: Positive Results
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Amgen announced today that the ADVANCE trial, a multicenter, randomized, placebo-controlled, double-blind Phase III study designed to assess the effectiveness and safety of Otezla ® (apremilast) treatment for mild moderate plaque psoriasis, has yielded positive top-line resultsThe results showed that oral apremilast improved significantly in the global assessment of static physicians (sPGAs) compared to placebos, with sPGAs at least 2 points lower than baselines at week 16in additionthe total score of the affected body surface area (BSA), psoriasis area and severity index (PASI) was significantly improved compared to the baseline at week 16The adverse events observed in this trial were consistent with Otezla's known safety, with the most common adverse events being diarrhea, headache, nausea, nasopharyngitis and upper respiratory tract infections"Many patients with mild to moderate plaque psoriasis who use topical therapy continue to face the challenge of treating psoriasis," said David MReese, executive vice president of research and development atAminWe look forward to discussing with the FDA bringing Otezla to more patients who need additional treatment options."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
